Doxorubicin Nanoparticles are an injectable drug made up of microscopic polymer based spheres containing the drug doxorubicin. Doxorubicin, a chemotherapy drug used to treat many types of cancer, slows or stops the growth of cancer cells by blocking an enzyme called topoisomerase 2.2 Studies on doxorubicin nanoparticles on people with advance HCC have suggested it may extend lifespan. If doxorubicin nanoparticles is licenced in the UK, it could provide a new treatment option for patients with advance HCC when other treatment options have failed, which may extend patient survival time.
Nivolumab works by improving the activity of white blood cells thereby increasing the ability of the immune system to kill cancer cells. Cabozantinib works to stop signals that cancer cells use to divide and grow. It is thought that when used in combination, both drugs may be more effective than each drug on its own. If licenced, nivolumab in combination with cabozantinib may improve long-term outcomes in mRCC patients who currently have limited treatment options.